Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2009

Hoeflich Klaus P, O'Brien Carol, Boyd Zachary, Cavet Guy, Guerrero Steve, Jung Kenneth, Januario Tom, Savage Heidi, Punnoose Elizabeth, Truong Tom, Zhou Wei, Berry Leanne, Murray Lesley, Amler Lukas, Belvin Marcia, Friedman Lori S, Lackner Mark R

Abstract excerpt

PURPOSE: The pathways underlying basal-like breast cancer are poorly understood, and as yet, there is no approved targeted therapy for this disease. We investigated the role of mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) inhibitors as targeted therapies for basal-like breast cancer. EXPERIMENTAL DESIGN: We used pharmacogenomic analysis of a large panel of breast cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mammary Neoplasms, Experimental
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred Strains

Share to Mice, Nude

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to PTEN Phosphohydrolase

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 19567590
DOI: 10.1158/1078-0432.CCR-09-0317

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.PMID 19567590Read ↗

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.Semantic proximity Read ↗

Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK InhibitionSemantic proximity Read ↗

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.Semantic proximity Read ↗

Genetically engineered mouse models of PI3K signaling in breast cancerSemantic proximity Read ↗

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cellsSemantic proximity Read ↗

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.Semantic proximity Read ↗

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.Semantic proximity Read ↗

EGFR associated expression profiles vary with breast tumor subtypeSemantic proximity Read ↗

Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cellsSemantic proximity Read ↗

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.Semantic proximity Read ↗

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer ModelsSemantic proximity Read ↗

Elevated PI3K signaling drives multiple Breast Cancer subtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.